Sign In
Buy CLLS
$3.09
-0.290 (-8.58%)
At Close: Jun 03, 2026
Monthly information on share capital and company voting rights
04:30pm, Wednesday, 03'rd Jun 2026
PARIS, June 03, 2026 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 Date Total number of shares in the capital Total number of voting rights 05/31/2026 100,691,658 106,134
Cellectis’ Annual Shareholders General Meeting to be Held on June 25, 2026
04:30pm, Wednesday, 20'th May 2026
NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develo
Cellectis' Annual Shareholders General Meeting to be Held on June 25, 2026
04:30pm, Wednesday, 20'th May 2026
NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to de
Cellectis to Present Clinical Data on Lasme-cel and Eti-cel at EHA 2026 Annual Congress
09:30am, Tuesday, 12'th May 2026
NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to d
Cellectis Reports Financial Results for the First Quarter 2026
04:30pm, Monday, 11'th May 2026
Pivotal Phase 2 with lasme-cel in r/r B-ALL (BALLI-01 trial) Pivotal Phase 2 first interim analysis expected in Q4 2026 BLA submission anticipated in 2028 Phase 1 with eti-cel in r/r NHL (NATHALI-01
Monthly information on share capital and company voting rights
04:30pm, Wednesday, 06'th May 2026
(Article 223-16 of General Regulation of the French financial markets authority) (Article 223-16 of General Regulation of the French financial markets authority)
Cellectis to Report First Quarter Financial Results on May 11, 2026
04:30pm, Monday, 04'th May 2026
NEW YORK, May 04, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to de
Cellectis Presents Epigenetic Editing Platform to Turn Genes Off Without Altering DNA at the ASGCT Annual Meeting
04:30pm, Monday, 27'th Apr 2026
NEW YORK, April 27, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to
NEW YORK, 13 avr. 2026 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), société de biotechnologie de stade clinique, qui utilise sa plateforme pionnière d'édition de génome p
Cema-Cel Pivotal Trial Interim Data Highlight Strength of Cellectis' Allogeneic CAR-T Platform
04:30pm, Monday, 13'th Apr 2026
NEW YORK, April 13, 2026 (GLOBE NEWSWIRE) -- Cellectis (or the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform
Monthly information on share capital and company voting rights
04:30pm, Tuesday, 07'th Apr 2026
(Article 223-16 of General Regulation of the French financial markets authority) (Article 223-16 of General Regulation of the French financial markets authority)
Cellectis S.A. (CLLS) Q4 2025 Earnings Call Transcript
01:02pm, Friday, 20'th Mar 2026
Cellectis S.A. (CLLS) Q4 2025 Earnings Call Transcript
Cellectis Reports Full Year 2025 Financial Results and Provides a Business Update
07:21pm, Thursday, 19'th Mar 2026
NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to
Cellectis to Report Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026
04:30pm, Thursday, 12'th Mar 2026
NEW YORK, March 12, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS, NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to
Monthly information on share capital and company voting rights
04:30pm, Wednesday, 04'th Mar 2026
(Article 223-16 of General Regulation of the French financial markets authority) (Article 223-16 of General Regulation of the French financial markets authority)
